---
document_datetime: 2026-01-07 16:14:04
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/norvir-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: norvir-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.5912174
conversion_datetime: 2026-01-10 11:18:40.381787
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.1
  docling: 2.67.0
  docling-core: 2.58.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Norvir

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C.I.11 Introduction of, or change(s) to, the | 07/01/2026                          |                                             |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000316673                     | obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.a Implementation of wording agreed by the competent authority - Accepted To update to bring the RMP in line with the information in the SmPC as adopted (EMA/VR/0000249795 - to modify the approved therapeutic indication to reflect current clinical use as a pharmacokinetic enhancer of other antiretroviral products only).                           |            |            |             |                                                                                |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000249795 | This was an application for a group of variations. C.I.6 Change(s) to therapeutic indication(s) - C.I.6.a Addition of a new therapeutic indication or modification of an approved one - Accepted B.II.f.1.a Reduction of the shelf life of the finished product - B.II.f.1.a.1 As packaged for sale - Accepted B.II.f.1 Change in the shelf-life or storage conditions of the finished product - B.II.f.1.e Change to an approved stability protocol - Accepted | 18/09/2025 | 03/11/2025 | SmPC and PL | Please refer to Scientific Discussion 'Norvir-H-C- 000127-II-EMA/VR/0000249795 |

<div style=\"page-break-after: always\"></div>

| (C.I.6.a): To modify the approved therapeutic indication to reflect current clinical use as a pharmacokinetic enhancer of other antiretroviral products only. Consequently, sections 4.1, 4.2, 4.3, 4.4, 4.5, 4.8 and 5.1 of the SmPC and the Package Leaflet are updated accordingly. The updated RMP version 8.0 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to the PI. Type IB (B.II.f.1.a.1): To reduce the shelf life of Norvir 100 mg powder for oral suspension as packaged for sale, from 36 months to 18 months and to reduce the shelf-life of Norvir 100 mg film-coated tablet from 2 years to 18 months. Type IB (B.II.f.1.e): To change the stability protocol of Norvir 100 mg powder for oral suspension to reflect updated long term testing intervals as a consequence of the reduction in shelf life. The group of variations leads to amendments to the annexes I and IIIB, and to the RMP.   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|